Publication

BEACON-Immuno: Results of the dinutuximab beta (dB) randomization of the BEACON-Neuroblastoma phase 2 trial-A European Innovative Therapies for Children with Cancer (ITCC-International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial

Gray, J.
; 
Moreno, L.
; 
Weston, R.
; 
Barone, G.
; 
Rubio, A.
; 
Makin, Guy
; 
Vaidya, S.
; 
Ng, A.
; 
Castel, V.
; 
Nysom, K.
... show 8 more
Citations
Altmetric:
Abstract
Authors
Gray, J.
Moreno, L.
Weston, R.
Barone, G.
Rubio, A.
Makin, Guy
Vaidya, S.
Ng, A.
Castel, V.
Nysom, K.
Laureys, G.
Van Eijkelenburg, N.
Owens, C.
Gambart, M.
Pearson, A. D. J.
Laidler, J.
Kearns, P.
Wheatley, K.
Affiliation
University of Southamtpon, Southampton
Description
Date
2022
Publisher
Collections
All Paterson Institute for Cancer Research
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Gray J, Moreno L, Weston R, Barone G, Rubio A, Makin G, et al. BEACON-Immuno: Results of the dinutuximab beta (dB) randomization of the BEACON-Neuroblastoma phase 2 trial-A European Innovative Therapies for Children with Cancer (ITCC-International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680300005.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/625792
Embedded videos